mardi 29 août 2017

Onco Actu du 29 août 2017

4. Dépistage, diagnostic et pronostic

The science myths that will not die [Nature]

STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts [BMJ]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Concept Paper on Development and Lifecycle of Personalised Medicines and Companion Diagnostics [ESMO]

5. Traitements

International Lenalidomide Trials Show Survival Benefit of Maintenance Therapy Following Transplant [Roswell Park Cancer Institute]

5.12.3 Immunothérapies-combinaisons

Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers [BMS]

Concurrent Treatment with OX40- and PD1-targeted Cancer Immunotherapies May be Detrimental [AACR]

Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers [Reuters]

5.2 Pharma

Aveo's phoenix drug tivozanib rises up in Europe [FierceBiotech]

Aveo takes a big step forward as comeback plan delivers EU OK for tivo [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

To Be More Than Quick Splash, Gilead’s CAR-T Purchase Faces Hurdles [Xconomy]

Kite's CAR-T medication, cancer candidates draw choosy Gilead for $12B pipeline-building buyout [FierceBiotech]

Gilead Overspends to Quiet Deal Clamor [Bloomberg]

Gilead-Kite: A Breakthrough. A $12 Billion Deal. Another Expensive Drug [Forbes]

Diving deep into CAR-T, Gilead forges $12B buyout deal for Kite Pharma [EndPoints]

Gilead Tries to Repeat Home Run With $11.9 Billion Kite Deal [Bloomberg]

5.3 Traitements - FDA, EMA, NICE...

Statement from FDA Commissioner Scott Gottlieb, M.D. on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine [FDA]

5.3.4 Traitements - AMM (FDA, EMA)

Two New Therapies Approved for Acute Myeloid Leukemia [NCI]

6.6 Publications

A New Way for Doctors to Share Their Medical Mysteries [Wired]

6.7.1 Bioinformatique

Why Everyone Is Hating on IBM Watson—Including the People Who Helped Make It [Gizmodo]